Evidence map›Paper›PMID 39365350›Full record

ReviewPathologie (Heidelberg, Germany)2024

[SARIFA-a new multi-entity biomarker].

Bianca Grosser, Nic G Reitsam, Przmyslaw Grochowski, Lukas Rentschler, Johanna Enke, Bruno Märkl

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bianca GrosserInstitut für Pathologie und Molekulare Diagnostik, Medizinische Fakultät Augsburg, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Deutschland.
Nic G ReitsamInstitut für Pathologie und Molekulare Diagnostik, Medizinische Fakultät Augsburg, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Deutschland.
Przmyslaw GrochowskiInstitut für Pathologie und Molekulare Diagnostik, Medizinische Fakultät Augsburg, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Deutschland.
Lukas RentschlerInstitut für Pathologie und Molekulare Diagnostik, Medizinische Fakultät Augsburg, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Deutschland.
Johanna EnkeKlinik für Nuklearmedizin, Medizinische Fakultät Augsburg, Universität Augsburg, Augsburg, Deutschland.
Bruno MärklInstitut für Pathologie und Molekulare Diagnostik, Medizinische Fakultät Augsburg, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Deutschland. bruno.maerkl@uka-science.de.ORCID http://orcid.org/0000-0002-7704-850X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A stroma a‑reactive invasion front area (SARIFA) is a new prognostic biomarker in carcinomas. Essentially, SARIFA describes the occurrence of direct contact between at least five tumor cells and adipocytes. This phenomenon is extremely easy and quick to identify, shows an extremely low interobserver variability, and does not require any additional staining as it can be identified on standard HE sections. The prognostic efficiency has now been demonstrated in gastric, colorectal, pancreatic, and prostate carcinoma.

Indexed as

Biomarkers, TumorNeoplasmsAdipocytesHumansNeoplasm InvasivenessPrognosisBiomarkers, TumorAdipocytesCarcinomaColorectal neoplasmsHistologyPrognosis

Identifiers

PMID39365350

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.